menu
    • menu
    [{"orgOrder":0,"company":"University of Oxford","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Macugen","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Oxford \/ Pfizer Inc"},{"orgOrder":0,"company":"Retina Institute of Hawaii","sponsor":"Eyetech Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Macugen","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Retina Institute of Hawaii","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Retina Institute of Hawaii \/ Eyetech Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Retina Institute of Hawaii \/ Eyetech Pharmaceuticals"},{"orgOrder":0,"company":"Valley Retina Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Macugen","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Valley Retina Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valley Retina Institute \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Valley Retina Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Macugen","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Macugen","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Macugen","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Pegaptanib Sodium

    Menu

    Pegaptanib Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bausch & Lomb Incorporated

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

                            Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 09, 2012

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Retina Institute of Hawaii

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Retina Institute of Hawaii

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Eyetech Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Ed...

                            Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 07, 2011

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Eyetech Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Valley Retina Institute

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Valley Retina Institute

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

                            Details : Macugen (Pegaptanib Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Retinopathy.

                            Product Name : Macugen

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2011

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pfizer Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema

                            Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 26, 2010

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of Oxford

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Oxford

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intravitreal Macugen for Ischaemic Diabetic Macular Oedema

                            Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 04, 2010

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pfizer Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects ...

                            Details : Pegaptanib Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 08, 2010

                            Lead Product(s) : Macugen

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth